Status:

COMPLETED

A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Myelogenous Leukemia, Chronic

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

In this study, the efficacy and safety of two nilotinib doses, 300 mg twice daily and 400 mg twice daily, were compared with imatinib 400 mg once daily in newly diagnosed patients with Philadelphia ch...

Detailed Description

Primary objectives of this study: * Compared the efficacy (major molecular response (MMR) rate at 12 months) of nilotinib at 400 mg bid with that of imatinib 400 mg qd in newly diagnosed, previously ...

Eligibility Criteria

Inclusion

  • Key Inclusion criteria:
  • Chronic myelogenous leukemia in chronic phase patients within the first 6 months of diagnosis.
  • Diagnosis of chronic myelogenous leukemia in chronic phase with confirmation of Philadelphia chromosome of (9:22) translocations
  • Key Exclusion criteria:
  • Previously documented T315I mutation
  • Treatment with a tyrosine kinase inhibitor prior to study entry is not allowed except for no more than 2 weeks in duration of imatinib
  • Any medical treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide
  • Impaired cardiac function.
  • Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection).
  • Use of therapeutic coumarin derivatives (i.e., warfarin, acenocoumarol, phenprocoumon)
  • Currently receiving treatment with any medications that have the potential to prolong the QT interval.

Exclusion

    Key Trial Info

    Start Date :

    July 31 2007

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    August 21 2019

    Estimated Enrollment :

    846 Patients enrolled

    Trial Details

    Trial ID

    NCT00471497

    Start Date

    July 31 2007

    End Date

    August 21 2019

    Last Update

    November 18 2020

    Active Locations (213)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 54 (213 locations)

    1

    University of California at Los Angeles Dept. of Hematology Clinic

    Los Angeles, California, United States, 90095

    2

    Kaiser Permanente - California Southern Dept of Kaiser South 3

    San Diego, California, United States, 92120

    3

    Kaiser Permanente - California Northern Vallejo Med Center/Med Offices

    Vallejo, California, United States, 94589

    4

    Kaiser Permanente - California Northern Kaiser Med

    Vallejo, California, United States, 94609